Anne Bass, MD: Thromboembolic Events in Patients With Rheumatic Disease
Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, explains why patients with rheumatic diseases are at risk for thromboembolism.
Transcript:
Why are thromboembolic events a special concern for patients with rheumatic disease?
So, we’ve learned that there’s a strong connection between the immune system inflammation and the clotting system. When your immune system is active, it actually makes you more prone to clotting. When patients have rheumatic diseases—not so much when they’re quiet, but when they’re active—almost any rheumatic disease, they’re at higher risk for blood clotting. It’s particularly true of conditions like granulomatosis with polyangiitis, which we used to call Wegener’s, but it’s really been shown to be the case with any rheumatic disease, including rheumatoid arthritis, for example, where the risk is about 2 and a half times when your disease is active than it would be if you didn’t have rheumatoid arthritis.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Dr Joseph Alvarnas Highlights the Current State of the Oncology Biosimilar Market
November 9th 2022Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope, explains what the recent FDA approvals of Stimufend and Vegzelma, 2 oncology biosimilars, says about the current state of the oncology biosimilar space.
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
April 12th 2022Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among adalimumab biosimilars when they enter the US market in 2023.
